Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01712685 · ClinicalTrials.gov registry record · Phase 2

Imaging Studies of Kidney Cancer Using 18F-VM4-037

A Phase 2 study, sponsored by National Cancer Institute (NCI).

Terminated
Registry status
Phase 2
Development phase
12
Enrollment target

NCT01712685: Clinical Trial Phase 2 study, sponsored by National Cancer Institute (NCI).

NCT01712685 is a Phase 2 study that was terminated before completion, run by National Cancer Institute (NCI). The registered enrollment target is 12 participants. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01712685, a Phase 2 study, was terminated before completion, sponsored by National Cancer Institute (NCI).

TERMINATED
Registry status
Phase 2
Development phase
12 participants
Enrollment target

Study Summary

Background: \- The drug 18F-VM4-037 is being tested for use in cancer imaging studies. It may help tumor tissue show up more clearly during scans. Researchers want to see how well it works for scans for people who have kidney cancer. Objectives: \- To test the safety and effectiveness of 18F-VM4-037 during imaging studies of kidney cancer. Eligibility: \- Adults at least 18 years of age with kidney cancer that will be treated with surgery. Design: * Participants will be screened with a physical exam and medical history. Blood and urine samples will be collected. * Participants will have two positron emission tomography (PET) scans of their kidneys. They will have the scans before and after receiving an injection of 18F-VM4-037. The scans will take about 2 hours to complete. * About 3 weeks after the PET scans, participants will provide tumor tissue samples from their kidneys. * This is a scanning study only. Treatment will not be provided as part of this study.

Interventions

  • PROCEDURE PET/CT
  • DRUG 18F-VM4-037

Trial Details

FieldValue
Enrollment Target 12 participants
Start Date 2012-10
Est. Completion 2013-08
Phase Phase 2

Sponsor

National Cancer Institute (NCI)

3,257 total trials

What the Registry Record Tells You About NCT01712685

The ClinicalTrials.gov registry entry for NCT01712685 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which PET/CT is the first listed.

NCT01712685 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT01712685 about?

NCT01712685 is a clinical study titled "Imaging Studies of Kidney Cancer Using 18F-VM4-037". Background: \- The drug 18F-VM4-037 is being tested for use in cancer imaging studies. It may help tumor tissue show up more clearly during scans. Researchers want to see how well it works for scans for people who have kidney cancer. Objectives: \- To test the safety and effectiveness of 18F-VM4-...

What is the current status of trial NCT01712685?

This trial is currently terminated. It is a Phase 2 study. The enrollment target is 12 participants. The study started on 2012-10. Estimated completion is 2013-08.

What interventions are being tested in trial NCT01712685?

The interventions under investigation include: PET/CT (PROCEDURE), 18F-VM4-037 (DRUG).

Who is sponsoring clinical trial NCT01712685?

This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.